Figure 4.
![SE-induced drug resistance is mediated by TCR signaling via LCK-PKC-NF-κB. Representative flow cytometric plots (SS4 [A]; SS13 [C,E]) and quantifications of percentage of viable malignant cells from PBMCs of patients with SS treated with 2 nM romidepsin for 72 hours in the presence or absence of SE and 2 μM A-419259 (A-B) (Src inhibitor) (n = 8 [SS4, SS5, SS8, SS10, SS12, SS13, SS14, and SS15]), 100 nM dasatinib (C-D) (n = 6 [SS4, SS8, SS10, SS12, SS13, and SS15]), and 1.5 μM sotrastaurin (E-F) (PKC inhibitor) (n = 5 [SS4, SS10, SS12, SS13, and SS15]). Statistical significance was assessed by repeated measures 1-way ANOVA followed by Tukey multiple comparison test. ∗P < .05; ∗∗P < .01; ∗∗∗∗P < .0001. DMSO, dimethyl sulfoxide.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/143/15/10.1182_blood.2023021671/3/blood_bld-2023-021671-gr4.jpeg?Expires=1735809471&Signature=Tn7r4p-WG77Wfn5zgihN-2MpEuGA8ooB4Y5aomsIA3778v568zM~MT994doNrN1XF7cKDyjH4YikhETjeEhbzjwDin4rHvNDdt7d46dC~C9H8VO3w~BlWh2dXZ2JpHg5mD4tct0E5NGS806t~OysBMLPzbi2m99Ie2BEmnOgKNdxxDAGPJKBxliwuDfEkNUgsYzPylyhqpXcI3tNw9nm1neHIr8jrL0FdZIacuStwavduITk76mrjb2MdTcyZlwTBz-JFjHAkNUan~3zFSoxvcWYFh~aXD3JN8Xj1IxxR8mh73p71HwUPPw~ebqJSf~COarnvzGnRZaHhOV864Qebw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
SE-induced drug resistance is mediated by TCR signaling via LCK-PKC-NF-κB. Representative flow cytometric plots (SS4 [A]; SS13 [C,E]) and quantifications of percentage of viable malignant cells from PBMCs of patients with SS treated with 2 nM romidepsin for 72 hours in the presence or absence of SE and 2 μM A-419259 (A-B) (Src inhibitor) (n = 8 [SS4, SS5, SS8, SS10, SS12, SS13, SS14, and SS15]), 100 nM dasatinib (C-D) (n = 6 [SS4, SS8, SS10, SS12, SS13, and SS15]), and 1.5 μM sotrastaurin (E-F) (PKC inhibitor) (n = 5 [SS4, SS10, SS12, SS13, and SS15]). Statistical significance was assessed by repeated measures 1-way ANOVA followed by Tukey multiple comparison test. ∗P < .05; ∗∗P < .01; ∗∗∗∗P < .0001. DMSO, dimethyl sulfoxide.
